P-036: Bone anabolic effect of ixazomib - a third generation proteasome inhibitor – in multiple myeloma patients

MLA

Marta Diaz-delCastillo, et al. “P-036: Bone Anabolic Effect of Ixazomib - a Third Generation Proteasome Inhibitor – in Multiple Myeloma Patients.” Clinical Lymphoma Myeloma and Leukemia, vol. 22, Aug. 2022, p. S55. EBSCOhost, https://doi.org/10.1016/s2152-2650(22)00366-4.

APA

Marta Diaz-delCastillo, Michael Gundesen, Christian Andersen, Anne Nielsen, Hanne EH Møller, Pernille Vinholt, Jon Asmussen, Ida Kristensen, Charlotte Nyvold, Niels Abildgaard, Thomas Andersen, & Thomas Lund. (2022). P-036: Bone anabolic effect of ixazomib - a third generation proteasome inhibitor – in multiple myeloma patients. Clinical Lymphoma Myeloma and Leukemia, 22, S55. https://doi.org/10.1016/s2152-2650(22)00366-4

Chicago

Marta Diaz-delCastillo, Michael Gundesen, Christian Andersen, Anne Nielsen, Hanne EH Møller, Pernille Vinholt, Jon Asmussen, et al. 2022. “P-036: Bone Anabolic Effect of Ixazomib - a Third Generation Proteasome Inhibitor – in Multiple Myeloma Patients.” Clinical Lymphoma Myeloma and Leukemia 22 (August): S55. doi:10.1016/s2152-2650(22)00366-4.